(CercleFinance.com) – Novo Nordisk today announced the main results of a trial carried out on more than 17,000 adults aged 45 or over suffering from overweight or obesity and cardiovascular disease (CVD) without prior history. of diabetes.
The trial compared semaglutide 2.4 mg subcutaneously once a week with placebo, with the aim of preventing major adverse cardiovascular events (MACE) for up to five years.
The trial achieved its primary objective by demonstrating a statistically significant and greater reduction in MACE of 20% for those treated with semaglutide 2.4mg compared to placebo.
Additionally, semaglutide 2.4 mg appeared to have a safe and well-tolerated profile, consistent with previous trials of semaglutide 2.4 mg.
According to Martin Holst Lange, executive vice president of development at Novo Nordisk, this trial demonstrated that semaglutide 2.4 mg has the potential to change the way obesity is viewed and treated.
Novo Nordisk expects to file for regulatory approval for an extension of indication for semaglutide 2.4 mg (Wegovy®) in the US and EU in 2023.
Copyright (c) 2023 CercleFinance.com. All rights reserved.